Profound Medical Corp. (PROF)
| Market Cap | 251.21M +106.9% |
| Revenue (ttm) | 18.81M +58.6% |
| Net Income | -38.90M |
| EPS | -1.22 |
| Shares Out | 36.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,170 |
| Open | 6.80 |
| Previous Close | 6.90 |
| Day's Range | 6.80 - 6.81 |
| 52-Week Range | 3.76 - 8.95 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 11.14 (+63.58%) |
| Earnings Date | May 7, 2026 |
About PROF
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-t... [Read more]
Financial Performance
In 2025, Profound Medical's revenue was $16.10 million, an increase of 50.73% compared to the previous year's $10.68 million. Losses were -$42.57 million, 53.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PROF stock is "Strong Buy." The 12-month stock price target is $11.14, which is an increase of 63.58% from the latest price.
News
Telix announces LoI to collaborate with EDAP TMS and Profound Medical
Telix Pharmaceuticals (TLX) announces that it has entered into letters of intent, or LoI, to pursue collaborations with EDAP TMS (EDAP) and Profound Medical (PROF), companies developing advanced minim...
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative i...
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and...
Profound Medical Corp Annual Shareholders Meeting Transcript
Profound Medical Corp Annual Shareholders Meeting Transcript
Profound Medical files to sell 921,428 common shares for holders
17:07 EDT Profound Medical (PROF) files to sell 921,428 common shares for holders
Profound Medical Registration statement: Registration filing
Profound Medical filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Profound Medical Q1 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supp...
Profound Medical price target lowered to $10 from $12 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Profound Medical (PROF) to $10 from $12 and keeps a Buy rating on the shares.
Profound Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue doubled year-over-year to CAD 5.3 million, with improved gross margin and a narrowed net loss. Private insurer coverage expanded, clinical evidence strengthened, and 2026 revenue is guided to grow 56% to CAD 25 million, with margins of 70% or higher.
Profound Medical Earnings release: Q1 2026
Profound Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Profound Medical Quarterly report: Q1 2026
Profound Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
Profound Medical Reports Strong First Quarter 2026 Financial Results
– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORO...
Profound Medical Slides: Corporate presentation
Profound Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Profound Medical Corp (PROF) Q1 2026 Earnings Report Preview: What to Expect
Profound Medical Corp (PROF) Q1 2026 Earnings Report Preview: What to Expect
Profound Medical Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
TULSA, an AI-driven, MRI-guided, incision-free prostate therapy, is gaining traction with strong clinical data, expanding insurance coverage, and a growing addressable market in prostate cancer and BPH. High margins and partnerships with major MRI companies support robust financial growth.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are ad...
Profound Medical Slides: Corporate presentation
Profound Medical has posted slides in relation to its latest quarterly earnings report, which was published on April 21, 2026.
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...
Profound Medical Corp. Investigated by the Portnoy Law Firm
LOS ANGELES, April 09, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Profound Medical Corp. , (“ Profound " or the "Company") ( NASDAQ : PROF) investors that the firm has initiated an investi...
Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...
Top 3 Health Care Stocks That Are Set To Fly In March
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Profound Medical's (PROF) TULSA Procedure Shows Superior Safety Outcomes
Profound Medical's (PROF) TULSA Procedure Shows Superior Safety Outcomes
Profound Medical Transcript: Status update
CAPTAIN trial six-month data show TULSA offers superior safety, faster recovery, and better functional outcomes than surgery for intermediate-risk prostate cancer. TULSA's precision, flexibility, and growing evidence base support its inclusion in guidelines and broader adoption, with insurance coverage expected to improve as more data mature.
Profound Medical reports CAPTAIN trial meets primary safety endpoint
Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic rad...